Dewpoint Therapeutics

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Zhifei Commits To Acquiring $2.93bn Of

Deal volume was down last year both in M&A and alliances, but valuations rose. Early in 2023, Pfizer Inc. set the tone for a year of moving on from the COVID-19 pandemic by agreeing to pay $43bn for

Ascendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. New Vertex/CRISPR Pact Centers On Gene-